JP7009371B2 - バイオポリマーを脱アセチル化するための方法 - Google Patents
バイオポリマーを脱アセチル化するための方法 Download PDFInfo
- Publication number
- JP7009371B2 JP7009371B2 JP2018534174A JP2018534174A JP7009371B2 JP 7009371 B2 JP7009371 B2 JP 7009371B2 JP 2018534174 A JP2018534174 A JP 2018534174A JP 2018534174 A JP2018534174 A JP 2018534174A JP 7009371 B2 JP7009371 B2 JP 7009371B2
- Authority
- JP
- Japan
- Prior art keywords
- hydroxylamine
- glycosaminoglycan
- biopolymer
- acid
- deacetylated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims description 97
- 230000000850 deacetylating effect Effects 0.000 title claims description 10
- 229920001222 biopolymer Polymers 0.000 title description 139
- 229920002683 Glycosaminoglycan Polymers 0.000 claims description 184
- 229920002674 hyaluronan Polymers 0.000 claims description 117
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 111
- 229960003160 hyaluronic acid Drugs 0.000 claims description 111
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 90
- 238000006243 chemical reaction Methods 0.000 claims description 69
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 64
- 150000003839 salts Chemical class 0.000 claims description 60
- 239000000203 mixture Substances 0.000 claims description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 45
- 238000006640 acetylation reaction Methods 0.000 claims description 30
- 230000021736 acetylation Effects 0.000 claims description 26
- 229920001287 Chondroitin sulfate Polymers 0.000 claims description 24
- 229920002567 Chondroitin Polymers 0.000 claims description 20
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 claims description 20
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims description 19
- 229940059329 chondroitin sulfate Drugs 0.000 claims description 19
- 150000002443 hydroxylamines Chemical class 0.000 claims description 15
- 230000008569 process Effects 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 138
- 239000000047 product Substances 0.000 description 78
- 239000000017 hydrogel Substances 0.000 description 77
- 238000003381 deacetylation reaction Methods 0.000 description 57
- 239000000499 gel Substances 0.000 description 55
- 230000006196 deacetylation Effects 0.000 description 53
- 238000004132 cross linking Methods 0.000 description 49
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 48
- 125000003277 amino group Chemical group 0.000 description 32
- 239000002253 acid Substances 0.000 description 31
- 239000007864 aqueous solution Substances 0.000 description 28
- 239000011541 reaction mixture Substances 0.000 description 28
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 27
- 150000004676 glycans Chemical class 0.000 description 25
- 239000000243 solution Substances 0.000 description 25
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 24
- 239000003431 cross linking reagent Substances 0.000 description 24
- 229920001282 polysaccharide Polymers 0.000 description 21
- 239000005017 polysaccharide Substances 0.000 description 21
- BMTZEAOGFDXDAD-UHFFFAOYSA-M 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholin-4-ium;chloride Chemical compound [Cl-].COC1=NC(OC)=NC([N+]2(C)CCOCC2)=N1 BMTZEAOGFDXDAD-UHFFFAOYSA-M 0.000 description 20
- 239000003795 chemical substances by application Substances 0.000 description 20
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 18
- 238000005859 coupling reaction Methods 0.000 description 18
- 238000011282 treatment Methods 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 17
- 230000008878 coupling Effects 0.000 description 17
- 238000010168 coupling process Methods 0.000 description 17
- 230000015556 catabolic process Effects 0.000 description 16
- 239000007822 coupling agent Substances 0.000 description 16
- 238000006731 degradation reaction Methods 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- 239000003153 chemical reaction reagent Substances 0.000 description 15
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 14
- 125000003047 N-acetyl group Chemical group 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- 150000001408 amides Chemical class 0.000 description 13
- 239000008363 phosphate buffer Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 238000000354 decomposition reaction Methods 0.000 description 12
- 229910052500 inorganic mineral Inorganic materials 0.000 description 11
- 239000011707 mineral Substances 0.000 description 11
- 238000006386 neutralization reaction Methods 0.000 description 11
- 229920000642 polymer Polymers 0.000 description 11
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 10
- 125000003368 amide group Chemical group 0.000 description 10
- 150000001720 carbohydrates Chemical class 0.000 description 10
- -1 heparosan Polymers 0.000 description 10
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 10
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 9
- 150000007513 acids Chemical class 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 150000002148 esters Chemical class 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical group C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
- NAQMVNRVTILPCV-UHFFFAOYSA-N hexane-1,6-diamine Chemical compound NCCCCCCN NAQMVNRVTILPCV-UHFFFAOYSA-N 0.000 description 8
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 8
- 239000012026 peptide coupling reagents Substances 0.000 description 8
- 230000035484 reaction time Effects 0.000 description 8
- SHKUUQIDMUMQQK-UHFFFAOYSA-N 2-[4-(oxiran-2-ylmethoxy)butoxymethyl]oxirane Chemical compound C1OC1COCCCCOCC1CO1 SHKUUQIDMUMQQK-UHFFFAOYSA-N 0.000 description 7
- 208000016247 Soft tissue disease Diseases 0.000 description 7
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 7
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 7
- 230000004048 modification Effects 0.000 description 7
- 238000012986 modification Methods 0.000 description 7
- 150000007524 organic acids Chemical class 0.000 description 7
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 235000019260 propionic acid Nutrition 0.000 description 7
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 230000010933 acylation Effects 0.000 description 6
- 238000005917 acylation reaction Methods 0.000 description 6
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 6
- 229940099552 hyaluronan Drugs 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- ZNBNBTIDJSKEAM-UHFFFAOYSA-N 4-[7-hydroxy-2-[5-[5-[6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-3-methyloxolan-2-yl]-5-methyloxolan-2-yl]-2,8-dimethyl-1,10-dioxaspiro[4.5]decan-9-yl]-2-methyl-3-propanoyloxypentanoic acid Chemical compound C1C(O)C(C)C(C(C)C(OC(=O)CC)C(C)C(O)=O)OC11OC(C)(C2OC(C)(CC2)C2C(CC(O2)C2C(CC(C)C(O)(CO)O2)C)C)CC1 ZNBNBTIDJSKEAM-UHFFFAOYSA-N 0.000 description 5
- 239000004971 Cross linker Substances 0.000 description 5
- 229920002971 Heparan sulfate Polymers 0.000 description 5
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 5
- 150000001718 carbodiimides Chemical class 0.000 description 5
- 150000001735 carboxylic acids Chemical class 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000007863 gel particle Substances 0.000 description 5
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 5
- 229910000378 hydroxylammonium sulfate Inorganic materials 0.000 description 5
- 235000005985 organic acids Nutrition 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
- DGXQIOFXDWAWGZ-KLWMDXOYSA-N N-[(2R,3R,4S)-1,3,4,5-tetrahydroxy-6-trityloxyhexan-2-yl]acetamide Chemical compound CC(=O)N[C@H](CO)[C@@H](O)[C@H](O)C(O)COC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 DGXQIOFXDWAWGZ-KLWMDXOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 description 4
- 229920000249 biocompatible polymer Polymers 0.000 description 4
- 238000010382 chemical cross-linking Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229920000669 heparin Polymers 0.000 description 4
- 229960002897 heparin Drugs 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical group CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 229920000288 Keratan sulfate Polymers 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000012345 acetylating agent Substances 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000003513 alkali Substances 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- 125000002843 carboxylic acid group Chemical group 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 150000002016 disaccharides Chemical class 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- XCAJEXZWARSCGJ-UHFFFAOYSA-N n-[2-(4-aminophenyl)ethyl]acetamide Chemical compound CC(=O)NCCC1=CC=C(N)C=C1 XCAJEXZWARSCGJ-UHFFFAOYSA-N 0.000 description 3
- 235000006408 oxalic acid Nutrition 0.000 description 3
- 150000004804 polysaccharides Polymers 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
- ABFPKTQEQNICFT-UHFFFAOYSA-M 2-chloro-1-methylpyridin-1-ium;iodide Chemical group [I-].C[N+]1=CC=CC=C1Cl ABFPKTQEQNICFT-UHFFFAOYSA-M 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 229920000045 Dermatan sulfate Polymers 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 description 2
- HETCEOQFVDFGSY-UHFFFAOYSA-N Isopropenyl acetate Chemical compound CC(=C)OC(C)=O HETCEOQFVDFGSY-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical group CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- KPFBUSLHFFWMAI-HYRPPVSQSA-N [(8r,9s,10r,13s,14s,17r)-17-acetyl-6-formyl-3-methoxy-10,13-dimethyl-1,2,7,8,9,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1C[C@@H]2[C@](CCC(OC)=C3)(C)C3=C(C=O)C[C@H]2[C@@H]2CC[C@](OC(C)=O)(C(C)=O)[C@]21C KPFBUSLHFFWMAI-HYRPPVSQSA-N 0.000 description 2
- GPDHNZNLPKYHCN-DZOOLQPHSA-N [[(z)-(1-cyano-2-ethoxy-2-oxoethylidene)amino]oxy-morpholin-4-ylmethylidene]-dimethylazanium;hexafluorophosphate Chemical compound F[P-](F)(F)(F)(F)F.CCOC(=O)C(\C#N)=N/OC(=[N+](C)C)N1CCOCC1 GPDHNZNLPKYHCN-DZOOLQPHSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- AVJBPWGFOQAPRH-FWMKGIEWSA-N alpha-L-IdopA-(1->3)-beta-D-GalpNAc4S Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS(O)(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C(O)=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-N 0.000 description 2
- 238000010640 amide synthesis reaction Methods 0.000 description 2
- 229910052786 argon Inorganic materials 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000021615 conjugation Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 229940051593 dermatan sulfate Drugs 0.000 description 2
- 150000004985 diamines Chemical class 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 229940071870 hydroiodic acid Drugs 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- 230000000269 nucleophilic effect Effects 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 238000005897 peptide coupling reaction Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920000768 polyamine Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- MZSSNAXYSBVGDC-ATDZWHFBSA-N (2R,3R,4S)-2-amino-6-trityloxyhexane-1,3,4,5-tetrol Chemical compound N[C@H](CO)[C@H]([C@@H](C(COC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1)O)O)O MZSSNAXYSBVGDC-ATDZWHFBSA-N 0.000 description 1
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- ODIGIKRIUKFKHP-UHFFFAOYSA-N (n-propan-2-yloxycarbonylanilino) acetate Chemical compound CC(C)OC(=O)N(OC(C)=O)C1=CC=CC=C1 ODIGIKRIUKFKHP-UHFFFAOYSA-N 0.000 description 1
- FIDRAVVQGKNYQK-UHFFFAOYSA-N 1,2,3,4-tetrahydrotriazine Chemical compound C1NNNC=C1 FIDRAVVQGKNYQK-UHFFFAOYSA-N 0.000 description 1
- GXXXUZIRGXYDFP-UHFFFAOYSA-M 2-(4-methylphenyl)acetate Chemical compound CC1=CC=C(CC([O-])=O)C=C1 GXXXUZIRGXYDFP-UHFFFAOYSA-M 0.000 description 1
- XZXYQEHISUMZAT-UHFFFAOYSA-N 2-[(2-hydroxy-5-methylphenyl)methyl]-4-methylphenol Chemical compound CC1=CC=C(O)C(CC=2C(=CC=C(C)C=2)O)=C1 XZXYQEHISUMZAT-UHFFFAOYSA-N 0.000 description 1
- AOBIOSPNXBMOAT-UHFFFAOYSA-N 2-[2-(oxiran-2-ylmethoxy)ethoxymethyl]oxirane Chemical compound C1OC1COCCOCC1CO1 AOBIOSPNXBMOAT-UHFFFAOYSA-N 0.000 description 1
- GPIQOFWTZXXOOV-UHFFFAOYSA-N 2-chloro-4,6-dimethoxy-1,3,5-triazine Chemical compound COC1=NC(Cl)=NC(OC)=N1 GPIQOFWTZXXOOV-UHFFFAOYSA-N 0.000 description 1
- HEGWNIMGIDYRAU-UHFFFAOYSA-N 3-hexyl-2,4-dioxabicyclo[1.1.0]butane Chemical compound O1C2OC21CCCCCC HEGWNIMGIDYRAU-UHFFFAOYSA-N 0.000 description 1
- LNPMZQXEPNWCMG-UHFFFAOYSA-N 4-(2-aminoethyl)aniline Chemical compound NCCC1=CC=C(N)C=C1 LNPMZQXEPNWCMG-UHFFFAOYSA-N 0.000 description 1
- FUSNOPLQVRUIIM-UHFFFAOYSA-N 4-amino-2-(4,4-dimethyl-2-oxoimidazolidin-1-yl)-n-[3-(trifluoromethyl)phenyl]pyrimidine-5-carboxamide Chemical compound O=C1NC(C)(C)CN1C(N=C1N)=NC=C1C(=O)NC1=CC=CC(C(F)(F)F)=C1 FUSNOPLQVRUIIM-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 208000005422 Foreign-Body reaction Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- BZGOJWNJJOAGMM-CGQASKLYSA-N O[C@@H]1OC([C@H](C([C@@H]1NC(C)=O)O)O)COC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 Chemical compound O[C@@H]1OC([C@H](C([C@@H]1NC(C)=O)O)O)COC(C1=CC=CC=C1)(C1=CC=CC=C1)C1=CC=CC=C1 BZGOJWNJJOAGMM-CGQASKLYSA-N 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- SWLVFNYSXGMGBS-UHFFFAOYSA-N ammonium bromide Chemical compound [NH4+].[Br-] SWLVFNYSXGMGBS-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 229940107816 ammonium iodide Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 229940094517 chondroitin 4-sulfate Drugs 0.000 description 1
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 229940019765 dermatin Drugs 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical group C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- 239000011363 dried mixture Substances 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 150000002118 epoxides Chemical class 0.000 description 1
- 150000002168 ethanoic acid esters Chemical class 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N glucosamine group Chemical group OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 239000012493 hydrazine sulfate Substances 0.000 description 1
- 229910000377 hydrazine sulfate Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- GHQZZYYYHIPYPX-UHFFFAOYSA-N hydroxylamine;2,2,2-trifluoroacetic acid Chemical compound ON.OC(=O)C(F)(F)F GHQZZYYYHIPYPX-UHFFFAOYSA-N 0.000 description 1
- VYXJGNUQZPDIFM-UHFFFAOYSA-N hydroxylamine;hydroiodide Chemical compound I.ON VYXJGNUQZPDIFM-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000001483 monosaccharide substituent group Chemical group 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N n-(3,4,5,6-tetrahydroxy-1-oxohexan-2-yl)acetamide Chemical compound CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000000235 small-angle X-ray scattering Methods 0.000 description 1
- 238000001998 small-angle neutron scattering Methods 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 238000003746 solid phase reaction Methods 0.000 description 1
- 238000001370 static light scattering Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- CJYPZNINSWXZPV-UHFFFAOYSA-N tert-butyl n-[4-(2-acetamidoethyl)phenyl]carbamate Chemical compound CC(=O)NCCC1=CC=C(NC(=O)OC(C)(C)C)C=C1 CJYPZNINSWXZPV-UHFFFAOYSA-N 0.000 description 1
- 150000004044 tetrasaccharides Chemical class 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/02—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques
- C08J3/03—Making solutions, dispersions, lattices or gels by other methods than by solution, emulsion or suspension polymerisation techniques in aqueous media
- C08J3/075—Macromolecular gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B61/00—Other general methods
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C209/00—Preparation of compounds containing amino groups bound to a carbon skeleton
- C07C209/62—Preparation of compounds containing amino groups bound to a carbon skeleton by cleaving carbon-to-nitrogen, sulfur-to-nitrogen, or phosphorus-to-nitrogen bonds, e.g. hydrolysis of amides, N-dealkylation of amines or quaternary ammonium compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/0825—Preparations of compounds not comprising Si-Si or Si-cyano linkages
- C07F7/083—Syntheses without formation of a Si-C bond
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0072—Hyaluronic acid, i.e. HA or hyaluronan; Derivatives thereof, e.g. crosslinked hyaluronic acid (hylan) or hyaluronates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/24—Crosslinking, e.g. vulcanising, of macromolecules
- C08J3/246—Intercrosslinking of at least two polymers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J7/00—Chemical treatment or coating of shaped articles made of macromolecular substances
- C08J7/12—Chemical modification
- C08J7/14—Chemical modification with acids, their salts or anhydrides
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K5/00—Use of organic ingredients
- C08K5/04—Oxygen-containing compounds
- C08K5/09—Carboxylic acids; Metal salts thereof; Anhydrides thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/18—Fluorenes; Hydrogenated fluorenes
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
- C08J2305/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2405/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2401/00 or C08J2403/00
- C08J2405/08—Chitin; Chondroitin sulfate; Hyaluronic acid; Derivatives thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
- Transplantation (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Saccharide Compounds (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15202944.3 | 2015-12-29 | ||
EP15202944.3A EP3187510A1 (fr) | 2015-12-29 | 2015-12-29 | Réticulation de glucides |
EP16172254.1A EP3252082A1 (fr) | 2016-05-31 | 2016-05-31 | Procédé pour la désacétylation de biopolymères |
EP16172225.1 | 2016-05-31 | ||
EP16172241.8 | 2016-05-31 | ||
EP16172225.1A EP3252080A1 (fr) | 2016-05-31 | 2016-05-31 | Procédé de préparation de glycosaminoglycanes réticulés acylés |
EP16172254.1 | 2016-05-31 | ||
EP16172241.8A EP3252081A1 (fr) | 2016-05-31 | 2016-05-31 | Hydrolyse de liaisons esters de glycosaminoglycanes réticulés par des liaisons amides |
PCT/EP2016/082774 WO2017114861A1 (fr) | 2015-12-29 | 2016-12-28 | Procédé de désacétylation de biopolymères |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019500472A JP2019500472A (ja) | 2019-01-10 |
JP7009371B2 true JP7009371B2 (ja) | 2022-01-25 |
Family
ID=57680280
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018534153A Pending JP2019505506A (ja) | 2015-12-29 | 2016-12-28 | アミド結合を切断するための方法 |
JP2018534173A Active JP7015784B2 (ja) | 2015-12-29 | 2016-12-28 | 炭水化物架橋剤 |
JP2018534174A Active JP7009371B2 (ja) | 2015-12-29 | 2016-12-28 | バイオポリマーを脱アセチル化するための方法 |
JP2022008632A Active JP7353400B2 (ja) | 2015-12-29 | 2022-01-24 | 炭水化物架橋剤 |
JP2023150040A Pending JP2023164569A (ja) | 2015-12-29 | 2023-09-15 | 炭水化物架橋剤 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018534153A Pending JP2019505506A (ja) | 2015-12-29 | 2016-12-28 | アミド結合を切断するための方法 |
JP2018534173A Active JP7015784B2 (ja) | 2015-12-29 | 2016-12-28 | 炭水化物架橋剤 |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022008632A Active JP7353400B2 (ja) | 2015-12-29 | 2022-01-24 | 炭水化物架橋剤 |
JP2023150040A Pending JP2023164569A (ja) | 2015-12-29 | 2023-09-15 | 炭水化物架橋剤 |
Country Status (18)
Country | Link |
---|---|
US (13) | US10899894B2 (fr) |
EP (7) | EP3623390B1 (fr) |
JP (5) | JP2019505506A (fr) |
KR (3) | KR20180121493A (fr) |
CN (4) | CN108884173A (fr) |
BR (2) | BR112018013523B1 (fr) |
CA (2) | CA3010021C (fr) |
CY (2) | CY1123452T1 (fr) |
DK (3) | DK3397648T3 (fr) |
ES (3) | ES2812223T3 (fr) |
FI (1) | FI3623390T3 (fr) |
HU (3) | HUE050221T2 (fr) |
MX (2) | MX2018008111A (fr) |
PL (2) | PL3623390T3 (fr) |
PT (2) | PT3397651T (fr) |
RU (3) | RU2018126365A (fr) |
SI (3) | SI3623390T1 (fr) |
WO (5) | WO2017114859A1 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2018126365A (ru) | 2015-12-29 | 2020-01-30 | Гальдерма С.А. | Способ расщепления амидных связей |
PT3623390T (pt) | 2016-05-31 | 2023-10-27 | Galderma Sa | Reticulador de hidrato de carbono |
WO2019002372A1 (fr) * | 2017-06-28 | 2019-01-03 | Nestlé Skin Health Sa | Procédé de préparation d'un produit hydrogel |
WO2019121688A1 (fr) * | 2017-12-22 | 2019-06-27 | Nestlé Skin Health Sa | Produit en gel injectable |
EP3581168A1 (fr) * | 2018-06-15 | 2019-12-18 | Universiteit Utrecht Holding B.V. | Compositions à libération prolongée |
US20210230202A1 (en) * | 2018-09-10 | 2021-07-29 | The Regents Of The University Of California | Dithiolsaccharide mucolytic agents and uses thereof |
CN109206537B (zh) * | 2018-10-10 | 2021-04-09 | 华熙生物科技股份有限公司 | 一种乙酰化透明质酸钠的制备方法及其应用 |
EP3659632A1 (fr) * | 2018-11-29 | 2020-06-03 | Nestlé Skin Health SA | Dégradation partielle post-réticulation d'hydrogels d'amide réticulés |
EP3897763A1 (fr) * | 2018-12-21 | 2021-10-27 | Galderma Holding SA | Compositions d'hydrogel encapsulant des particules solides |
CN115335414B (zh) | 2019-12-02 | 2024-03-19 | 高德美控股有限公司 | 高分子量美容组合物 |
US20230172968A1 (en) * | 2020-04-17 | 2023-06-08 | Prohibix Llc | Controlled release hyaluronic acid compositions |
WO2023148619A1 (fr) | 2022-02-01 | 2023-08-10 | Galderma Holding SA | Procédés de production d'hydrogels à base acide hyaluronique réticulés |
WO2024057154A1 (fr) * | 2022-09-12 | 2024-03-21 | Glycocore Pharma S.R.L. | Procédé de conjugaison d'acide hyaluronique et conjugués d'acide hyaluronique ainsi obtenus |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002519481A (ja) | 1998-07-06 | 2002-07-02 | フィディア・アドバンスト・バイオポリマーズ・ソシエタ・ア・レスポンサビリタ・リミタータ | ヒアルロン酸アミドおよびそれらの誘導体、並びにそれらの製造法 |
WO2002082078A2 (fr) | 2001-04-09 | 2002-10-17 | Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. | Systemes de detection a enzyme liee activee pour detection et quantification d'acides nucleiques, d'antigenes, d'anticorps et d'autres analytes |
WO2002081739A2 (fr) | 2001-04-09 | 2002-10-17 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Analyse non enzymatique a liaison liposomique avec electrodes en reseau etroitement espacees (nel-ela) pour detecter et quantifier des acides nucleiques |
JP2004507588A (ja) | 2000-08-31 | 2004-03-11 | フィディア ファルマチェウティチ ソシエタ ペル アチオニ | ヒアルロン酸の新規架橋誘導体 |
JP2004511588A (ja) | 2000-10-10 | 2004-04-15 | エルジー・ライフ・サイエンシーズ・リミテッド | ヒアルロン酸の架橋結合型アミド誘導体及びその製造方法。 |
JP2009507103A (ja) | 2005-09-02 | 2009-02-19 | コルバー・ライフサイエンス・リミテツド | 架橋多糖およびタンパク質マトリックスならびにそれらの製造方法 |
WO2014072330A1 (fr) | 2012-11-06 | 2014-05-15 | Centre National De La Recherche Scientifique (Cnrs) | Hydrogel réagissant au glucose comprenant l'acide hyaluronique (ha) sur lequel est greffé pba |
WO2015021092A1 (fr) | 2013-08-07 | 2015-02-12 | Arrowhead Research Corporation | Polyconjugués pour l'administration de déclencheurs d'arni à des cellules tumorales in vivo |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU730695A1 (ru) * | 1977-07-05 | 1980-04-30 | Ордена Ленина Институт Элементоорганических Соединений Ан Ссср | Способ получени хитозана |
EP0224987B1 (fr) * | 1985-11-29 | 1992-04-15 | Biomatrix, Inc. | Systèmes à base de l'hyaluronanne, de ses dérivés et de ses sels pour la libération de médicaments et leur procédé de fabrication |
JPS62265998A (ja) | 1986-03-10 | 1987-11-18 | ボ−ド オブ リ−ジエンツ ザ ユニヴア−シテイ オブ テキサス システム | ヘパラン硫酸エンドグリコシダーゼアッセイ |
US4859581A (en) * | 1986-03-10 | 1989-08-22 | Board Of Regents, The University Of Texas System | Endoglycosidase assay |
DE4200080A1 (de) * | 1992-01-03 | 1993-09-30 | Reinmueller Johannes | Pharmazeutische Zusammensetzung zur Wund-, Narben- und Keloidbehandlung |
JP2855307B2 (ja) * | 1992-02-05 | 1999-02-10 | 生化学工業株式会社 | 光反応性グリコサミノグリカン、架橋グリコサミノグリカン及びそれらの製造方法 |
DE4439575A1 (de) | 1994-11-05 | 1996-05-09 | Permselect Ges Fuer Zellstrukt | Neue Vernetzungsprodukte auf Basis Hyaluronsäure |
WO1997011958A1 (fr) | 1995-09-29 | 1997-04-03 | The Scripps Research Institute | Analyse de signature de proteine |
FR2764514B1 (fr) | 1997-06-13 | 1999-09-03 | Biopharmex Holding Sa | Implant injectable en sous-cutane ou intradermique a bioresorbabilite controlee pour la chirurgie reparatrice ou plastique et la dermatologie esthetique |
JP4385152B2 (ja) | 1997-09-17 | 2009-12-16 | 三菱化学株式会社 | 2価反応性水溶性高分子誘導体及びそれを含有する複合体 |
KR19990029749A (ko) * | 1997-09-17 | 1999-04-26 | 미우라 아끼라 | 2가 반응성 수용성 고분자 유도체 및 이들을 함유하는 복합체 |
FR2777193B1 (fr) | 1998-04-14 | 2001-06-08 | Coletica | Particule a groupement hydroxamique chelatante d'ions metalliques et leur utilisation en cosmetique ou en pharmacie |
US6630457B1 (en) | 1998-09-18 | 2003-10-07 | Orthogene Llc | Functionalized derivatives of hyaluronic acid, formation of hydrogels in situ using same, and methods for making and using same |
IT1303735B1 (it) | 1998-11-11 | 2001-02-23 | Falorni Italia Farmaceutici S | Acidi ialuronici reticolati e loro usi medici. |
GB9902412D0 (en) | 1999-02-03 | 1999-03-24 | Fermentech Med Ltd | Process |
GB9902652D0 (en) | 1999-02-05 | 1999-03-31 | Fermentech Med Ltd | Process |
AU2001277937A1 (en) | 2000-07-21 | 2002-02-05 | Diadexus, Inc. | Compositions and methods relating to lung specific genes |
BR0210722A (pt) | 2001-06-29 | 2004-07-20 | Medgraft Microtech Inc | Implantes injetáveis biodegradáveis e métodos relacionados de produção e uso |
FR2826657B1 (fr) | 2001-06-29 | 2003-09-05 | Rhodia Chimie Sa | Polymeres derives de polysaccharides comprenant une ou plusieurs fonctions oxime ou amine et utilisations desdits polymeres |
US8524884B2 (en) | 2001-10-30 | 2013-09-03 | Colorado State University Research Foundation | Outer layer material having entanglement of hydrophobic polymer hostblended with a maleated hydrophobic polymer co-host, and hydrophilic polymer guest |
KR20040009891A (ko) | 2002-07-26 | 2004-01-31 | 주식회사 엘지생명과학 | 히알루론산의 유도체 겔 및 그 제조방법 |
PT102888B (pt) | 2002-12-23 | 2005-04-29 | Filipe Manuel Rodrigues Aguiar | Processo industrial de producao de acido polilactico (pla) obtido por esterificacao e polimerizacao de acido lactico purificado, sendo o referido acido produzido atraves de um processo fermentativo |
TWI251596B (en) | 2002-12-31 | 2006-03-21 | Ind Tech Res Inst | Method for producing a double-crosslinked hyaluronate material |
US7115388B2 (en) | 2003-03-14 | 2006-10-03 | National Institute Of Agrobiological Sciences | Production of functional polypeptides originating from silk protein and use thereof |
US20160106717A1 (en) | 2004-09-24 | 2016-04-21 | Gen Pharma Holdings LLC | Cai-based systems and methods for the localized treatment of uveitis |
DE102005055385A1 (de) | 2004-12-09 | 2006-06-14 | Bayer Healthcare Ag | Arzneimittel zur hygienischen Applikation im Ohr |
US8241656B2 (en) | 2005-09-21 | 2012-08-14 | Surmodics, Inc | Articles including natural biodegradable polysaccharides and uses thereof |
DE102006013594A1 (de) | 2006-03-22 | 2007-09-27 | Biopolymer Gmbh & Co. Kg | Quervernetzte Gele von Hyaluronsäure und deren Verwendung |
ITRM20080636A1 (it) | 2008-11-28 | 2010-05-29 | Univ Palermo | Procedimento per la produzione di derivati funzionalizzati dell acido ialuronico e relativi idrogeli. |
WO2010065784A2 (fr) * | 2008-12-03 | 2010-06-10 | Jakk Group, Inc. | Procédés, dispositifs et compositions pour un remplissage dermique |
US10105197B1 (en) | 2009-03-26 | 2018-10-23 | Fernando Colon | Method of treatment for periodontal pockets |
WO2010115081A2 (fr) * | 2009-04-02 | 2010-10-07 | Allergan, Inc. | Hydrogels en forme de cheveu pour augmentation des tissus mous |
CN102070786B (zh) * | 2009-11-19 | 2012-05-30 | 中国农业科学院农产品加工研究所 | 一种透明质酸-海藻酸钠复合水凝胶及其制备方法 |
US8197849B2 (en) * | 2010-02-12 | 2012-06-12 | National Health Research Institutes | Cross-linked oxidated hyaluronic acid for use as a vitreous substitute |
KR101831918B1 (ko) | 2010-06-11 | 2018-02-27 | 한국원자력의학원 | 히알루론산의 탈아세틸화 가수분해효소, 및 이에 의해 탈아세틸화된 히알루론산 및 이의 유도체 |
EP2609924A4 (fr) | 2010-08-23 | 2014-01-22 | Denki Kagaku Kogyo Kk | Composition d'acide hyaluronique réticulé et particules d'acide hyaluronique s'auto-réticulant |
EP3184553B1 (fr) | 2011-03-03 | 2019-05-01 | Chugai Seiyaku Kabushiki Kaisha | Dérivé d'acide hyaluronique modifié avec un acide amino-carboxylique |
SG11201400444VA (en) * | 2011-09-07 | 2014-04-28 | Prolynx Llc | Hydrogels with biodegradable crosslinking |
KR102168028B1 (ko) | 2011-12-08 | 2020-10-20 | 알러간 인더스트리 에스에이에스 | 진피 필러 조성물 |
US8887243B2 (en) | 2012-01-30 | 2014-11-11 | Cisco Technology, Inc. | Integrated security platform |
CZ304512B6 (cs) * | 2012-08-08 | 2014-06-11 | Contipro Biotech S.R.O. | Derivát kyseliny hyaluronové, způsob jeho přípravy, způsob jeho modifikace a použití |
CN102952281B (zh) | 2012-09-13 | 2014-03-19 | 江苏隆源生物科技有限公司 | 一种壳寡糖和透明质酸交联凝胶的制备方法 |
US9597826B2 (en) * | 2012-10-30 | 2017-03-21 | Bell Helicopter Textron Inc. | Method of repairing, splicing, joining, machining, and stabilizing honeycomb core using pourable structural foam and a structure incorporating the same |
CN104140541A (zh) * | 2013-05-10 | 2014-11-12 | 北京化工大学 | 注射型透明质酸水凝胶的制备方法及其应用 |
CN105377899B (zh) | 2013-07-08 | 2017-12-01 | 电化株式会社 | 核壳型交联透明质酸凝胶颗粒、其制造方法和医用材料 |
US9518630B2 (en) * | 2013-08-01 | 2016-12-13 | Specialized Bicycle Components, Inc. | Bicycle air spring |
CN105658633A (zh) | 2013-09-03 | 2016-06-08 | 新加坡科技研究局 | 用于生物医药应用的聚合物-类黄酮缀合物和水凝胶 |
CN103788222B (zh) | 2014-01-08 | 2016-08-31 | 中国科学院昆明植物研究所 | Fuc3S4S取代的低聚糖胺聚糖及其制备方法 |
WO2015181365A1 (fr) | 2014-05-29 | 2015-12-03 | Galderma S.A. | Acide hyaluronique à greffe de cyclodextrine réticulé avec un dextrane et ses utilisations |
JP2017517601A (ja) | 2014-05-29 | 2017-06-29 | ガルデルマ エス.エー. | デキストランによりグラフト化された架橋ヒアルロン酸 |
CN104194066B (zh) * | 2014-09-15 | 2016-08-24 | 中国科学院上海硅酸盐研究所 | 氧化硅-壳聚糖复合气凝胶及其制备方法 |
CN105288594A (zh) * | 2015-11-30 | 2016-02-03 | 武汉理工大学 | 一种被可注射水凝胶包裹的生长因子多孔微球复合系统 |
RU2018126365A (ru) | 2015-12-29 | 2020-01-30 | Гальдерма С.А. | Способ расщепления амидных связей |
WO2019002368A1 (fr) | 2017-06-28 | 2019-01-03 | Nestlé Skin Health Sa | Glycosaminoglycanes réticulés et fonctionnalisés |
WO2019001784A1 (fr) | 2017-06-28 | 2019-01-03 | Nestlé Skin Health Sa | Gel d'acide hyaluronique avec un cation divalent |
WO2019002370A1 (fr) | 2017-06-28 | 2019-01-03 | Nestlé Skin Health Sa | Glycosaminoglycanes réticulés et fonctionnalisés |
US10889894B2 (en) * | 2018-08-06 | 2021-01-12 | Applied Materials, Inc. | Faceplate with embedded heater |
-
2016
- 2016-12-28 RU RU2018126365A patent/RU2018126365A/ru not_active Application Discontinuation
- 2016-12-28 US US16/066,985 patent/US10899894B2/en active Active
- 2016-12-28 RU RU2018126376A patent/RU2748235C2/ru active
- 2016-12-28 EP EP19204239.8A patent/EP3623390B1/fr active Active
- 2016-12-28 US US16/066,793 patent/US11198765B2/en active Active
- 2016-12-28 US US16/066,967 patent/US11066526B2/en active Active
- 2016-12-28 EP EP16822477.2A patent/EP3397651B1/fr active Active
- 2016-12-28 HU HUE16822477A patent/HUE050221T2/hu unknown
- 2016-12-28 BR BR112018013523-2A patent/BR112018013523B1/pt active IP Right Grant
- 2016-12-28 SI SI201631754T patent/SI3623390T1/sl unknown
- 2016-12-28 CN CN201680077070.4A patent/CN108884173A/zh active Pending
- 2016-12-28 JP JP2018534153A patent/JP2019505506A/ja active Pending
- 2016-12-28 JP JP2018534173A patent/JP7015784B2/ja active Active
- 2016-12-28 KR KR1020187021913A patent/KR20180121493A/ko not_active Application Discontinuation
- 2016-12-28 WO PCT/EP2016/082770 patent/WO2017114859A1/fr active Application Filing
- 2016-12-28 ES ES16819582T patent/ES2812223T3/es active Active
- 2016-12-28 SI SI201630860T patent/SI3397651T1/sl unknown
- 2016-12-28 MX MX2018008111A patent/MX2018008111A/es unknown
- 2016-12-28 ES ES19204239T patent/ES2962687T3/es active Active
- 2016-12-28 EP EP16819582.4A patent/EP3397648B1/fr active Active
- 2016-12-28 WO PCT/EP2016/082783 patent/WO2017114867A1/fr active Application Filing
- 2016-12-28 FI FIEP19204239.8T patent/FI3623390T3/fi active
- 2016-12-28 PL PL19204239.8T patent/PL3623390T3/pl unknown
- 2016-12-28 DK DK16819582.4T patent/DK3397648T3/da active
- 2016-12-28 CN CN201680082707.9A patent/CN108779184B/zh active Active
- 2016-12-28 HU HUE16819582A patent/HUE050124T2/hu unknown
- 2016-12-28 WO PCT/EP2016/082778 patent/WO2017114864A1/fr active Application Filing
- 2016-12-28 US US16/066,746 patent/US11254792B2/en active Active
- 2016-12-28 US US16/066,810 patent/US11530301B2/en active Active
- 2016-12-28 RU RU2018126372A patent/RU2733145C2/ru active
- 2016-12-28 KR KR1020187021912A patent/KR20180121492A/ko unknown
- 2016-12-28 WO PCT/EP2016/082774 patent/WO2017114861A1/fr active Application Filing
- 2016-12-28 WO PCT/EP2016/082781 patent/WO2017114865A1/fr active Application Filing
- 2016-12-28 EP EP16829091.4A patent/EP3397652A1/fr not_active Withdrawn
- 2016-12-28 CA CA3010021A patent/CA3010021C/fr active Active
- 2016-12-28 ES ES16822477T patent/ES2810013T3/es active Active
- 2016-12-28 CA CA3010161A patent/CA3010161C/fr active Active
- 2016-12-28 BR BR112018013504-6A patent/BR112018013504B1/pt active IP Right Grant
- 2016-12-28 PT PT168224772T patent/PT3397651T/pt unknown
- 2016-12-28 MX MX2018008110A patent/MX2018008110A/es unknown
- 2016-12-28 DK DK16822477.2T patent/DK3397651T3/da active
- 2016-12-28 HU HUE19204239A patent/HUE063918T2/hu unknown
- 2016-12-28 EP EP16822476.4A patent/EP3397650A1/fr active Pending
- 2016-12-28 PT PT168195824T patent/PT3397648T/pt unknown
- 2016-12-28 PL PL16822477T patent/PL3397651T3/pl unknown
- 2016-12-28 EP EP16819583.2A patent/EP3397649B1/fr active Active
- 2016-12-28 CN CN201680076930.2A patent/CN108884172A/zh active Pending
- 2016-12-28 CN CN202310345813.3A patent/CN116284867A/zh active Pending
- 2016-12-28 JP JP2018534174A patent/JP7009371B2/ja active Active
- 2016-12-28 DK DK19204239.8T patent/DK3623390T3/da active
- 2016-12-28 EP EP23188831.4A patent/EP4279537A3/fr active Pending
- 2016-12-28 SI SI201630877T patent/SI3397648T1/sl unknown
- 2016-12-28 KR KR1020187021919A patent/KR20180120142A/ko not_active Application Discontinuation
-
2020
- 2020-07-23 CY CY20201100677T patent/CY1123452T1/el unknown
- 2020-08-06 CY CY20201100731T patent/CY1123455T1/el unknown
- 2020-12-21 US US17/129,366 patent/US11708461B2/en active Active
-
2021
- 2021-12-13 US US17/549,450 patent/US20220169804A1/en active Pending
-
2022
- 2022-01-24 JP JP2022008632A patent/JP7353400B2/ja active Active
- 2022-02-21 US US17/676,675 patent/US20220177655A1/en active Pending
- 2022-11-29 US US18/071,282 patent/US11643509B2/en active Active
-
2023
- 2023-03-15 US US18/184,439 patent/US11780970B2/en active Active
- 2023-06-12 US US18/208,527 patent/US11939433B2/en active Active
- 2023-09-05 US US18/242,468 patent/US20230416469A1/en active Pending
- 2023-09-15 JP JP2023150040A patent/JP2023164569A/ja active Pending
-
2024
- 2024-02-28 US US18/590,007 patent/US20240199822A1/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002519481A (ja) | 1998-07-06 | 2002-07-02 | フィディア・アドバンスト・バイオポリマーズ・ソシエタ・ア・レスポンサビリタ・リミタータ | ヒアルロン酸アミドおよびそれらの誘導体、並びにそれらの製造法 |
JP2004507588A (ja) | 2000-08-31 | 2004-03-11 | フィディア ファルマチェウティチ ソシエタ ペル アチオニ | ヒアルロン酸の新規架橋誘導体 |
JP2004511588A (ja) | 2000-10-10 | 2004-04-15 | エルジー・ライフ・サイエンシーズ・リミテッド | ヒアルロン酸の架橋結合型アミド誘導体及びその製造方法。 |
WO2002082078A2 (fr) | 2001-04-09 | 2002-10-17 | Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. | Systemes de detection a enzyme liee activee pour detection et quantification d'acides nucleiques, d'antigenes, d'anticorps et d'autres analytes |
WO2002081739A2 (fr) | 2001-04-09 | 2002-10-17 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Analyse non enzymatique a liaison liposomique avec electrodes en reseau etroitement espacees (nel-ela) pour detecter et quantifier des acides nucleiques |
JP2009507103A (ja) | 2005-09-02 | 2009-02-19 | コルバー・ライフサイエンス・リミテツド | 架橋多糖およびタンパク質マトリックスならびにそれらの製造方法 |
WO2014072330A1 (fr) | 2012-11-06 | 2014-05-15 | Centre National De La Recherche Scientifique (Cnrs) | Hydrogel réagissant au glucose comprenant l'acide hyaluronique (ha) sur lequel est greffé pba |
WO2015021092A1 (fr) | 2013-08-07 | 2015-02-12 | Arrowhead Research Corporation | Polyconjugués pour l'administration de déclencheurs d'arni à des cellules tumorales in vivo |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7009371B2 (ja) | バイオポリマーを脱アセチル化するための方法 | |
EP3187510A1 (fr) | Réticulation de glucides | |
EP3252081A1 (fr) | Hydrolyse de liaisons esters de glycosaminoglycanes réticulés par des liaisons amides | |
EP3252082A1 (fr) | Procédé pour la désacétylation de biopolymères | |
EP3252080A1 (fr) | Procédé de préparation de glycosaminoglycanes réticulés acylés |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180829 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20191108 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201005 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201217 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210517 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210915 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20210915 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20211109 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20211115 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211213 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220112 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7009371 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |